1. IntroductionThe global weight-management pharmaceutical industry is witnessing an important development with the introduction of oral weight-loss medicines. Until recently, patients interested in GLP-1 (glucagon-like peptide-1)-based treatments for obesity generally had to depend on weekly injections. However, a new development has created an alternative: a daily tablet containing semaglutide, marketed under the brand name Wegovy.On 3 November 2026, Australia's Therapeutic Goods Administration (TGA) approved the oral version of Wegovy for use in the country. This makes it the first GLP-1 weight-loss medicine approved in Australia in tablet form.Manufactured by Danish pharmaceutical company Novo Nordisk, the medicine is expected to provide
